Pharmaceutical PV DIV - FSB
Ended Awarded Last action
- Contract number
- SPE2DU26FENXK
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,273
Award facts
- Contract value 100% obligated
- $13,272.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $13,272.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This delivery order, issued on December 5, 2025, with an ultimate completion date of December 8, 2025, represents a purchase of pharmaceutical products and medical consumables from DMS Pharmaceutical Group's inventory. The award was made without a set-aside designation, indicating the vendor competed in an unrestricted procurement process. DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, with particular focus on supporting Department of Defense medical operations.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $499.999 billion acquisition vehicle established on November 13, 2025, with performance extending through December 31, 2036. The PPV-G GEN V contract is structured as a 30-month base period with three 30-month option periods and authorizes DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, vaccines, and medical consumables to support military healthcare facilities worldwide. DMS Pharmaceutical Group's product portfolio encompasses oncology treatments, immunosuppressants, emergency medications, specialty surgical products, and routine pharmaceuticals, positioning the company as a key regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy.
Quick answers
Who was awarded contract SPE2DU26FENXK?
SPE2DU26FENXK was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 5, 2025.
How much is contract SPE2DU26FENXK worth?
The government has obligated $13,273 on SPE2DU26FENXK.
Is contract SPE2DU26FENXK an order under another contract?
Yes. SPE2DU26FENXK is a delivery order under SPE2DU25D9418, an indefinite delivery contract.
Was contract SPE2DU26FENXK competed?
The extent of competition for SPE2DU26FENXK was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award